Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
FeaturedIPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, face sharp criticism for misquoting statutory provisions and misinterpreting Section 3(d) of the Patents Act. Experts warn the draft could undermine patent stability and prosecution consistency if adopted without revision.
FeaturedThe Indian Patent Office’s Draft Guidelines for Examination of Pharmaceutical Patent Applications (2026) face strong criticism for misquoting statutory provisions and misinterpreting legal standards. Stakeholders call for substantial revision before finalization.
FeaturedThe Delhi High Court, in Fresenius Kabi v. Controller, set aside the rejection of a patent application for Sugammadex, citing procedural flaws under Section 14 of the Patents Act. The Court criticized the use of hindsight and mosaicking in prior art analysis.
FeaturedThe Delhi High Court set aside the Controller’s refusal of Fresenius Kabi’s Sugammadex patent, citing procedural flaws under Section 14 of the Patents Act. The order underscores strict compliance with hearing requirements and warns against hindsight bias in inventive step analysis.
Delhi High Court upheld the rejection of a patent for 'Co-crystals of Tramadol and Coxibs' for lack of inventive step, while affirming novelty. The decision clarifies the threshold for non-obviousness in pharmaceutical innovations.
The Indian Patent Office’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, have drawn sharp criticism for misquoting statutory provisions and creating uncertainty in patent prosecution. Experts call for substantial revision before finalization.
The IPO’s Draft Guidelines for Pharmaceutical Patents (2026) face criticism for misquoting statutes and misinterpreting Indian patent law. Experts call for urgent revision to prevent disruption.
IPO’s Draft Guidelines for Pharmaceutical Patent Examination face criticism for statutory misquotations and misinterpretations. Experts warn they could disrupt prosecution if not substantially revised.
The IPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, have drawn strong criticism for misquoting statutory provisions and introducing legally unsound interpretations. Stakeholders urge comprehensive revision before finalization.
The Delhi High Court has addressed critical aspects of pharmaceutical patent law in the case of Intra Cellular Therapies v. Controller of Patents, revisiting coverage disclosure and the therapeutic efficacy threshold under Section 3(d).
IPO's 2026 Draft Guidelines for Pharma Patents contain misquotations and misinterpretations, say experts. Flawed approach risks disrupting patent examination standards.
The IPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026 face severe criticism for misquoting provisions and misinterpreting patentability standards, raising concerns over examination consistency and legal accuracy.